Anti‐programmed cell death‐1 antibody as a new serological marker for type 1 autoimmune hepatitis
Authors:
- 22 July 2013
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 29 (1) , 110-115
Abstract
Background and Aim: Recently, the association of the dysfunction of programmed cell death (PD)‐1 expressed on activated lymphocytes with the pathogenesis of autoimmune hepatitis (AIH) has been speculated. This study aimed to investigate the association of serum anti‐PD‐1 antibodies with clinical characteristics of type 1 AIH.Methods: Serum samples before the initiation of prednisolone treatment were obtained from 52 type 1 AIH patients, 24 patients with drug‐induced liver injury (DILI), 30 patients with acute viral hepatitis (AVH), 11 patients with primary sclerosing cholangitis (PSC), and 62 healthy volunteers. Titers of serum anti‐PD‐1 antibodies were measured by indirect enzyme‐linked immunosorbent assay. The cutoff level was represented by a mean absorbance + 2 standard deviations in healthy volunteers.Results: Prevalence of serum anti‐PD‐1 antibodies was 63% in type 1 AIH patients, 8% in DILI patients, 13% in AVH patients, 18% in PSC patients, and 3% in healthy volunteers. In type 1 AIH patients, titers of serum anti‐PD‐1 antibodies were correlated with serum levels of bilirubin (r = 0.31, P = 0.030) and alanine aminotransferase (r = 0.31, P = 0.027) but not serum immunoglobulin G levels. Positivity for serum anti‐PD‐1 antibodies was associated with the later normalization of serum alanine aminotransferase levels after the initiation of prednisolone and the disease relapse.Conclusions: Serum anti‐PD‐1 antibodies would be useful for the discrimination of type 1 AIH from DILI, AVH, and PSC as an auxiliary diagnostic marker. Furthermore, anti‐PD‐1 antibodies may be associated with clinical characteristics of type 1 AIH.Keywords
This publication has 30 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion VaccineJournal of Immunotherapy, 2011
- Present status of autoimmune hepatitis in Japan: a nationwide surveyJournal of Gastroenterology, 2011
- Programmed Death-1 Antibody Blocks Therapeutic Effects of T-Regulatory Cells in Cockroach Antigen-Induced Allergic AsthmaAmerican Journal of Respiratory Cell and Molecular Biology, 2010
- B and T Lymphocyte Attenuator Is Highly Expressed on CMV-Specific T Cells during Infection and Regulates Their FunctionThe Journal of Immunology, 2010
- Autoantibodies and the Risk of Cardiovascular EventsThe Journal of Rheumatology, 2009
- Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease†Hepatology, 2009
- Enhancing SIV-specific immunity in vivo by PD-1 blockadeNature, 2008
- Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitisJournal of Hepatology, 2005
- International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitisJournal of Hepatology, 1999